-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

259 Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical Gvhd Models

Program: Oral and Poster Abstracts
Type: Oral
Session: 701. Experimental Transplantation: Basic and Translational: GVHD, Mucosal Immunology and the Microbiome
Hematology Disease Topics & Pathways:
Research, Adult, Translational Research, GVHD, Diseases, Immune Disorders, Metabolism, Biological Processes, Microbiome, Study Population, Human, Animal model
Saturday, December 7, 2024: 2:00 PM

Jenny Paredes, PhD1, Teng Fei, PhD2*, Anqi Dai, MS3*, Ruben Ramos, PhD3*, Peter Adintori, MS3*, Anastasia Kousa, PhD4*, Chi L Nguyen, PhD4*, Kristen Victor3*, Romina Ghale3*, Charlotte Pohl, BA3*, Harold K Elias, MD3,5, Oriana Miltiadous, MD3*, Sebastien Monette6*, Ana Gradissimo, PhD3*, Justin Cross, PhD3*, Jonathan U. Peled, MD, PhD7, Marina Burgos da Silva, PhD8* and Marcel R.M. van den Brink, MD, PhD1

1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
2Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
3Memorial Sloan Kettering Cancer Center, New York, NY
4City of Hope National Medical Center, Duarte, CA
5National Institutes of Health, Bethesda, MD
6MSKCC, New York, NY
7Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
8Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York

Background: Dietary fiber can modulate the intestinal microbiome and increase the production of short-chain fatty acids (SCFAs), and bile acids (BAs) which are beneficial microbial metabolites associated with intestinal homeostasis. To investigate the effects of dietary fiber on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (allo-HCT), we evaluated a preclinical mouse model of GVHD with defined diet fiber concentrations and analyzed the dietary patterns of allo-HCT patients. We hypothesized that a high-fiber diet in allo-HCT recipients could increase intestinal microbiome diversity, the concentration of beneficial microbial metabolites, and decreased risk of GVHD.

Methods: We collected high-resolution dietary data at Memorial Sloan Kettering Cancer Center (173 allo-HCT patients), from 10 days pre-transplantation to 30 days post-transplantation (3,837 patient days), 16S rRNA sequencing data of fecal samples (1,028 patient days), and gas chromatography-mass spectrometry (GC-MS) data of fecal SCFA concentration for a sub-cohort of acute lower-GI-GVHD patients (110 patient days) and no-GVHD patients (128 patient days) matched by stool sample availability.

We investigated the associations between longitudinal fiber intake and microbial markers (longitudinal data analysis, generalized estimating equations), including α-diversity, butyrate producers, and concentrations of fecal SCFAs between lower-GI-GVHD and no-GVHD patients. To account for high variation in patients’ dietary intake trajectories and macronutrients interactions, we performed latent trajectory class analysis to identify patient’s dietary intake patterns and to correlate fiber intake and patient survival.

We evaluated how dietary fiber can affect GVHD in a preclinical mouse GVHD model (C57BL/6J into BALB/c) treated with cellulose at 0%, 6%, 12% and 40% concentrations and assessed survival (n=180, n=30 per group), fecal microbial composition by shotgun sequencing (n=165), SCFA concentrations by GC-MS (n=32, n=8 group), immune composition by flow cytometry (n=45, n=15 group) and, the gene expression of cells from the lamina propria of mouse colons by single cell sequencing (scSeq) (n=9, n=3 group).

Results: In allo-HCT patients, a higher fiber intake was significantly associated with a higher microbial α-diversity (p=0.009), a higher abundance of butyrate producers (p=0.03), and a higher concentration of butyrate (p=0.02). Lower GI-GVHD patients had a significantly lower fecal concentrations of butyrate (p=0.03) and acetate (p=0.02) after adjustment for fiber intake. The latent trajectory class analysis identified two patient groups: high fiber (HF) and low fiber (LF) intake, where the HF group had a significantly better overall survival (log-rank p=0.04) and lower cumulative incidence of acute lower GI-GVHD (Gray’s p=0.04).

In our preclinical GVHD model, we determined that mice receiving a fiber-rich diet (12% cellulose) had a significant reduction in GVHD lethality (p=0.02), higher microbial α-diversity (p=0.02), decreased relative abundance of the pathogenic bacteria Enterococcus faecalis (p=0.001 vs. 0%), a higher ratio of regulatory T cells (CD4+CD25+FOXP3+) over conventional T cells (CD4+) (p=0.008; p=0.001) and a higher concentration of cecal butyrate (p=0.03 vs. 0%; p=0.03 vs. 6%). Importantly, scSeq analysis of CD4+ T cells in the 12% cellulose diet evinced a significant increase in the expression of genes associated with reduced GVHD, including IDO1 (indoleamine 2, 3-dioxygenase), and CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1), as well as the enrichment of the bile acid pathway and associated genes (p=0.01 vs. 0%; p=0.006 vs. 6%) including the farnesoid X-activated receptor NR4A1.

Conclusions: We demonstrated that higher fiber intake in patients after allo-HCT is associated with a) an increase in overall survival; b) a decrease in lower GI-aGVHD cumulative incidence; c) an increase in microbial α-diversity and butyrate-producers; and d) an increase in the fecal concentrations of SCFAs. In addition, the consumption of a 12% cellulose diet in a pre-clinical GVHD model leads to an increase in α-diversity, a decrease in pathogen relative abundance, an increase in Treg/Tconventional ratio, and a decrease in GVHD lethality. These results suggest that dietary fiber could be used in the prevention of GVHD.

Disclosures: Peled: Seres Therapeutics: Patents & Royalties, Research Funding; DaVolterra: Consultancy; CSL Behring: Consultancy; Crestone Inc: Consultancy; MaaT Pharma: Consultancy; Canaccord Genuity, Inc: Consultancy; Postbiotics Plus Research: Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Prodigy Biosciences: Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH